Tower Research Capital (TRC)’s Anebulo Pharmaceuticals ANEB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,230
| Closed | -$3.26K | – | 5105 |
|
|
2025
Q4 | $3.26K | Buy |
3,230
+1,480
| +85% | +$3.38K | ﹤0.01% | 4395 |
|
|
2025
Q3 | $4.38K | Sell |
1,750
-1,502
| -46% | -$3.53K | ﹤0.01% | 4362 |
|
|
2025
Q2 | $4.68K | Sell |
3,252
-286
| -8% | -$326 | ﹤0.01% | 4283 |
|
|
2025
Q1 | $4.6K | Buy |
3,538
+212
| +6% | +$312 | ﹤0.01% | 4233 |
|
|
2024
Q4 | $5.59K | Buy |
3,326
+632
| +23% | +$1.04K | ﹤0.01% | 4269 |
|
|
2024
Q3 | $5.2K | Sell |
2,694
-606
| -18% | -$1.29K | ﹤0.01% | 4311 |
|
|
2024
Q2 | $9.01K | Sell |
3,300
-1,838
| -36% | -$4.67K | ﹤0.01% | 4299 |
|
|
2024
Q1 | $14.7K | Sell |
5,138
-3,964
| -44% | -$10.2K | ﹤0.01% | 3291 |
|
|
2023
Q4 | $22K | Sell |
9,102
-11,749
| -56% | -$27.6K | ﹤0.01% | 3587 |
|
|
2023
Q3 | $63.7K | Buy |
20,851
+14,750
| +242% | +$40.9K | ﹤0.01% | 2345 |
|
|
2023
Q2 | $14.3K | Buy |
6,101
+994
| +19% | +$2.48K | ﹤0.01% | 3708 |
|
|
2023
Q1 | $15K | Buy |
5,107
+1,510
| +42% | +$4.29K | ﹤0.01% | 3759 |
|
|
2022
Q4 | $9K | Sell |
3,597
-3,733
| -51% | -$9.83K | ﹤0.01% | 4156 |
|
|
2022
Q3 | $21K | Buy |
7,330
+189
| +3% | +$671 | ﹤0.01% | 3882 |
|
|
2022
Q2 | $37K | Buy |
7,141
+6,385
| +845% | +$26.7K | ﹤0.01% | 3158 |
|
|
2022
Q1 | $5K | Buy |
+756
| New | +$5.18K | ﹤0.01% | 5012 |
|
|
2021
Q4 | – | Sell |
-39
| Closed | – | – | 6107 |
|
|
2021
Q3 | $0 | Sell |
39
-119
| -75% | -$834 | ﹤0.01% | 5739 |
|
|
2021
Q2 | $1K | Buy |
+158
| New | +$1.18K | ﹤0.01% | 5165 |
|
Tower Research Capital (TRC)'s ANEB Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 3,230 shares — an estimated $3.26K sold.
Tower Research Capital (TRC) first reported a position in ANEB in Q2 2021 and held it in 18 quarters. The position peaked at $63.7K in Q3 2023. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,230 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $3.26K.
- Tower Research Capital (TRC) first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 18 quarters.
- Tower Research Capital (TRC)'s Anebulo Pharmaceuticals position peaked at $63.7K in Q3 2023.
- 0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.